<DOC>
	<DOCNO>NCT02010593</DOCNO>
	<brief_summary>This study evaluate safety dapivirine vaginal ring insert every 4 week postmenopausal woman 12 week product use .</brief_summary>
	<brief_title>Safety Pharmacokinetics Dapivirine Vaginal Ring Post-menopausal Women</brief_title>
	<detailed_description>Dapivirine , non-nucleoside reverse-transcriptase inhibitor ( NNRTI ) , substitute diamino- pyrimidine ( DAPY ) derivative potent antiviral activity HIV-1 . Dapivirine chemically describe 4- [ [ 4- [ ( 2,4,6-trimethylphenyl ) amino ] -2- pyrimidinyl ] amino ] benzonitrile.6 The dapivirine matrix VR flexible ring contain 25 mg drug substance disperse platinum-catalyzed-cured silicone matrix . Dapivirine know well-suited delivery via VR , evidence favorable safety pharmacokinetic data date describe .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . Age 45 65 year ( inclusive ) Screening , verify per site SOPs 2 . Per participant report , postmenopausal Screening , define amenorrheaic past 12 month ( minimum ) least 6 month status postbilateral oophorectomy 3 . Folliclestimulating hormone ( FSH ) level 40 mIU/ml high Screening 4 . Able willing provide write informed consent screen enrolled MTN024/IPM 031 5 . Able communicate speak write English 6 . Able willing comply study procedural requirement 7 . Willing use study provide and/or approve vaginal product throughout duration study participation . 8 . Willing abstain inserting study approve lubricant vagina 72 hour prior visit 9 . Willing abstain vaginal intercourse 72 hour prior visit 10 . In general good health determine Investigator Record ( IoR ) /designee Screening Enrollment 11 . Able willing provide adequate locator information , define site SOPs 12 . HIVuninfected base test perform Screening ( per protocol algorithm Appendix II ) 13 . Per participant report Screening Enrollment , agree use male latex condom sexual intercourse 14 . Per participant report Screening Enrollment , state willingness refrain insert nonstudy vaginal product object vagina include , limited spermicide , female condom , diaphragm , topical systemic hormone replacement therapy , include vaginal estrogen , and/or hormonal contraceptive , vaginal medication , menstrual cup , cervical cap ( vaginal barrier method ) , vaginal douche , lubricant moisturizers , sex toy ( vibrator , dildo , etc . ) , duration study participation . Note : Use study approve lubricant permit . 15 . At Screening Enrollment , agree participate research study involve drug , medical device , vaginal product , vaccine duration study participation Participants biopsy subset must also meet follow criterion Screening eligible inclusion : 16 . Willing abstain insert anything vagina 72 hour follow collection biopsy , include abstain vaginal intercourse 17 . Anatomy sufficient collection cervical biopsy 1 . Per participant report screening : 1 . Plans relocate away study site study participation 2 . Plans travel away study site 4 consecutive week study participation 2 . Pregnant screen Note : A documented negative pregnancy test perform study staff require inclusion ; however selfreported pregnancy adequate exclusion study . 3 . Diagnosed urinary tract infection ( UTI ) Screening Enrollment Note : Otherwise eligible participant diagnose UTI screen offer treatment may enrol complete treatment symptom resolve . If treatment complete symptom resolve within 45 day obtain informed consent screening , participant may enrol . 4 . Diagnosed pelvic inflammatory disease , STI reproductive tract infection ( RTI ) require treatment per current Centers Disease Control Prevention ( CDC ) guideline Screening Enrollment Note : Otherwise eligible participant diagnose screen pelvic inflammatory disease STI/RTI require treatment per CDC guideline — asymptomatic bacterial vaginosis ( BV ) asymptomatic candidiasis — offer treatment may enrol complete treatment symptom resolve . If treatment complete symptom resolve within 45 day obtain informed consent screening , participant may enrol . Genital warts require treatment also must treat prior Enrollment . Genital warts require therapy define cause undue burden discomfort participant , include bulky size , unacceptable appearance , physical discomfort . 5 . Has clinically apparent Grade 2 high pelvic exam finding ( observe study staff ) Screening Enrollment , per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) , Addendum 1Female Genital Grading Table Use Microbicide Studies Note : Cervical bleeding associate speculum insertion and/or specimen collection judge within range normal accord clinical judgment Investigator Record ( IoR ) /designee consider expect nonmenstrual bleeding exclusionary . Note : Otherwise eligible participant exclusionary pelvic exam finding may enrolled/randomized finding improve nonexclusionary severity grade resolve . If improvement nonexclusionary grade resolution document within 45 day provide informed consent screening , participant may enrol . 6 . Participant report and/or clinical evidence follow : 1 . Known adverse reaction study product ( ever ) 2 . Known adverse reaction latex ( ever ) 3 . Chronic and/or recurrent vaginal candidiasis 4 . Topical systemic hormone replacement therapy and/or hormonal contraception within 6 month prior Enrollment 5 . Nontherapeutic injection drug use 12 month prior Enrollment 6 . Postexposure prophylaxis ( PEP ) HIV exposure within 6 month prior Enrollment 7 . Preexposure prophylaxis ( PrEP ) HIV prevention within 6 month prior Enrollment 8 . Last pregnancy outcome 6 month less prior Enrollment 9 . Gynecologic genital procedure ( e.g. , tubal ligation , dilation curettage , pierce ) 90 day less prior Enrollment 10 . Currently breastfeed 11 . At Screening , severe pelvic relaxation either vaginal wall uterine cervix descend beyond vaginal introitus valsalva maneuver 12 . Participation research study involve drug , medical device , vaginal product , vaccine , 45 day prior Enrollment 7 . As determined IoR/designee , significant uncontrolled active chronic cardiovascular , renal , liver , hematologic , neurologic , gastrointestinal , psychiatric , endocrine , respiratory , immunologic disorder infectious disease 8 . Has follow laboratory abnormality Screening Visit : 1 . Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) Grade 1 higher* 2 . Creatinine Grade 2 higher* 3 . Hemoglobin Grade 2 higher* 4 . Platelet count Grade 1 higher* 5 . Pap result Grade 2 higher** Note : Otherwise eligible participant exclusionary test may retested screen process . Note : Women document normal result within 12 month prior Enrollment need Pap smear screening period . Women Grade 1 abnormal Pap smear enrol upon completion initial phase evaluation current treatment indicate ( base local standard care management abnormal cervical cytology ) . Need repeat Pap within 6 month preclude Enrollment prior result become available . If participant hysterectomy reason related cervical dysplasia , Pap smear need perform . 9 . Has condition , opinion IoR/designee , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective *Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) **Female Genital Grading Table Use Microbicide Studies Addendum 1 Division AIDS ( DAIDS ) Table Grading Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 )</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>